Bi­par­ti­san House group calls on FDA to en­sure OTC and pre­scrip­tion ver­sions of a drug can­not be mar­ket­ed si­mul­ta­ne­ous­ly

Reps. Deb­bie Din­gell (D-MI), Robert Lat­ta (R-OH) and Dan Cren­shaw (R-TX) sent a let­ter yes­ter­day to Pa­trizia Cavaz­zoni, the head of FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search, call­ing on the agency to not fi­nal­ize a rule that would al­low for the si­mul­ta­ne­ous mar­ket­ing of OTC and pre­scrip­tion ver­sions of the same drug.

The rep­re­sen­ta­tives said the pro­pos­al “flies in the face of a decades-old law to pre­vent this from oc­cur­ring: When two prod­ucts are used for the same con­di­tion, with the same in­di­ca­tion, same dose, same strength, same form, and same route of ad­min­is­tra­tion, they ought to have the same le­gal clas­si­fi­ca­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER